

**TRIAMTERENE AND HYDROCHLOROTHIAZIDE- triamterene and hydrochlorothiazide capsule
REMEDYREPACK INC.**


**Triamterene and Hydrochlorothiazide Capsules, USP
Rx only**

DESCRIPTION

Each capsule of triamterene and hydrochlorothiazide for oral use, with opaque yellow cap and opaque white body, contains triamterene 37.5 mg and hydrochlorothiazide 25 mg, and is imprinted with 855. Hydrochlorothiazide is a diuretic/antihypertensive agent and triamterene is an antikaliuretic agent.


Hydrochlorothiazide, USP is very slightly soluble in water. It is freely soluble in sodium hydroxide solution, n-butylamine and dimethyl formamide. It is sparingly soluble in methanol. It is insoluble in ether, chloroform and dilute mineral acids.

Hydrochlorothiazide, USP is 6-chloro-3,4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide, and its structural formula is:



Triamterene, USP is soluble in formic acid. It is sparingly soluble in methoxyethanol. It is very slightly soluble in acetic acid, alcohol and dilute mineral acids. It is practically insoluble in water, benzene, ether, chloroform and dilute alkali hydroxides.

Triamterene, USP is 2, 4, 7-triamino-6-phenylpteridine and its structural formula is:



Each triamterene and hydrochlorothiazide capsule, USP intended for oral administration contains 37.5 mg triamterene USP with 25 mg hydrochlorothiazide USP. In addition, each capsule contains the following inactive ingredients: citric acid monohydrate, colloidal silicon dioxide, croscarmellose sodium, gelatin, glycine, hypromellose, iron oxide yellow, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and titanium dioxide. Each capsule is printed with black pharmaceutical ink which contains ferric oxide black, potassium hydroxide and shellac.

Capsules of triamterene and hydrochlorothiazide meet Drug Release Test 3 as published in the current USP monograph for Triamterene and Hydrochlorothiazide Capsules.

CLINICAL PHARMACOLOGY

Triamterene and hydrochlorothiazide capsule is a diuretic/antihypertensive drug product that combines natriuretic and antikaliuretic effects. Each component complements the action of the other. The hydrochlorothiazide component blocks the reabsorption of sodium and chloride ions, and thereby increases the quantity of sodium traversing the distal tubule and the volume of water excreted. A portion of the additional sodium presented to the distal tubule is exchanged there for potassium and hydrogen ions. With continued use of hydrochlorothiazide and depletion of sodium, compensatory mechanisms tend to increase this exchange and may produce excessive loss of potassium, hydrogen, and chloride ions. Hydrochlorothiazide also decreases the excretion of calcium and uric acid, may increase the excretion of iodide, and may reduce glomerular filtration rate. The exact mechanism of the antihypertensive effect of hydrochlorothiazide is not known.

The triamterene component of triamterene and hydrochlorothiazide capsules exerts its diuretic effect on the distal renal tubule to inhibit the reabsorption of sodium in exchange for potassium and hydrogen ions. Its natriuretic activity is limited by the amount of sodium reaching its site of action. Although it blocks the increase in this exchange that is stimulated by mineralocorticoids (chiefly aldosterone), it is not a competitive antagonist of aldosterone and its activity can be demonstrated in adrenalectomized rats and patients with Addison's disease. As a result, the dose of triamterene required is not proportionally related to the level of mineralocorticoid activity but is dictated by the response of the individual patients and the kaliuretic effect of concomitantly administered drugs. By inhibiting the distal tubular exchange mechanism, triamterene maintains or increases the sodium excretion and reduces the excess loss of potassium, hydrogen, and chloride ions induced by hydrochlorothiazide. As with hydrochlorothiazide, triamterene may reduce glomerular filtration and renal plasma flow. Via this mechanism, it may reduce uric acid excretion although it has no tubular effect on uric acid reabsorption or secretion. Triamterene does not affect calcium excretion. No predictable antihypertensive effect has been demonstrated for triamterene.

Duration of diuretic activity and effective dosage range of the hydrochlorothiazide and triamterene components of triamterene and hydrochlorothiazide capsules are similar. Onset of diuresis with triamterene and hydrochlorothiazide takes place within 1 hour, peaks at 2 to 3 hours, and tapers off during the subsequent 7 to 9 hours.

Triamterene and hydrochlorothiazide capsules are well absorbed.

Upon administration of a single oral dose to fasted normal male volunteers, mean

pharmacokinetic parameters were determined (Table 1).

Table 1. Mean Pharmacokinetic Parameters after Single Oral Dose in Fasted Male Volunteers ^a

	AUC (0-48) ng*h/mL (\pmSD)	C_{max} ng/mL (\pmSD)	Median T_{max} h	Ae Mg (\pmSD)
Triamterene	148.7 (87.9)	46.4 (29.4)	1.1	2.7 (1.4)
Hydroxytriamterene sulfate	1,865 (471)	720 (364)	1.3	19.7 (6.1)
Hydrochlorothiazide	834 (177)	135.1 (35.7)	2	14.3 (3.8)

^aAUC (0-48), C_{max}, T_{max}, and Ae represent area under the plasma concentration versus time plot, maximum plasma concentration, time to reach C_{max}, and amount excreted in urine over 48 hours.

A capsule of triamterene and hydrochlorothiazide is bioequivalent to a single entity 25-mg hydrochlorothiazide tablet and 37.5-mg triamterene capsule used in the double-blind clinical trial below (see Clinical Trials).

In a limited study involving 12 subjects, coadministration of triamterene and hydrochlorothiazide capsules with a high-fat meal resulted in: (1) an increase in the mean bioavailability of triamterene by about 67% (90% confidence interval = 0.99, 1.90), p-hydroxytriamterene sulfate by about 50% (90% confidence interval = 1.06, 1.77), hydrochlorothiazide by about 17% (90% confidence interval = 0.90, 1.34); (2) increases in the peak concentrations of triamterene and p-hydroxytriamterene; and (3) a delay of up to 2 hours in the absorption of the active constituents.

CLINICAL TRIALS

A placebo-controlled, double-blind trial was conducted to evaluate the efficacy of triamterene and hydrochlorothiazide capsules. This trial demonstrated that triamterene and hydrochlorothiazide capsules (37.5 mg triamterene/25 mg hydrochlorothiazide) were effective in controlling blood pressure while reducing the incidence of hydrochlorothiazide-induced hypokalemia. This trial involved 636 patients with mild to moderate hypertension controlled by hydrochlorothiazide 25 mg daily and who had hypokalemia (serum potassium <3.5 mEq/L) secondary to the hydrochlorothiazide. Patients were randomly assigned to 4 weeks' treatment with once-daily regimens of 25 mg hydrochlorothiazide plus placebo, or 25 mg hydrochlorothiazide combined with one of the following doses of triamterene: 25 mg, 37.5 mg, 50 mg, or 75 mg.

Blood pressure and serum potassium were monitored at baseline and throughout the trial. All 5 treatment groups had similar mean blood pressure and serum potassium concentrations at baseline (mean systolic blood pressure range: 137 \pm 14 mmHg to 140 \pm 16 mmHg; mean diastolic blood pressure range: 86 \pm 9 mmHg to 88 \pm 8 mmHg; mean serum potassium range: 2.3 to 3.4 mEq/L with the majority of patients having values between 3.1 and 3.4 mEq/L).

While all triamterene regimens reversed hypokalemia, at Week 4 the 37.5-mg regimen proved optimal compared with the other tested regimens. On this regimen, 81% of the

patients had a significant ($P<0.05$) reversal of hypokalemia vs. 59% of patients on the placebo/hydrochlorothiazide regimen. The mean serum potassium concentration on 37.5 mg triamterene went from 3.2 ± 0.2 mEq/L at baseline to 3.7 ± 0.3 mEq/L at Week 4, a significantly greater ($P<0.05$) improvement than that achieved with placebo/hydrochlorothiazide (i.e., 3.2 ± 0.2 mEq/L at baseline and 3.5 ± 0.4 mEq/L at Week 4). Also, 51% of patients in the 37.5-mg triamterene group had an increase in serum potassium of ≥ 0.5 mEq/L at Week 4 vs. 33% in the placebo group. The 37.5-mg triamterene/25-mg hydrochlorothiazide regimen also maintained control of blood pressure; mean supine systolic blood pressure at Week 4 was 138 ± 21 mmHg while mean supine diastolic blood pressure was 87 ± 13 mmHg.

INDICATIONS AND USAGE

This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.

Triamterene and hydrochlorothiazide capsules are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.

Triamterene and hydrochlorothiazide capsules are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked.

Triamterene and hydrochlorothiazide capsules may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide capsules may enhance the action of these agents, dosage adjustments may be necessary.

Usage in Pregnancy

The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.

Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.

CONTRAINDICATIONS

Antikaliuretic Therapy and Potassium Supplementation

Triamterene and hydrochlorothiazide capsules should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. Concomitant potassium-containing salt substitutes should also not be used.

Potassium supplementation should not be used with triamterene and hydrochlorothiazide capsules except in severe cases of hypokalemia. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.

Impaired Renal Function

Triamterene and hydrochlorothiazide capsules are contraindicated in patients with anuria, acute and chronic renal insufficiency, or significant renal impairment.

Hypersensitivity

Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication.

Hyperkalemia

Triamterene and hydrochlorothiazide capsules should not be used in patients with pre-existing elevated serum potassium.

WARNINGS

Hyperkalemia

Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing diuretic combinations, including triamterene and hydrochlorothiazide capsules. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment) and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients first receiving triamterene and hydrochlorothiazide capsules, when dosages are changed, or with any illness that may influence renal function.

If hyperkalemia is suspected (warning signs include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, and shock), an electrocardiogram (ECG) should be obtained. However, it is important to monitor serum potassium levels because hyperkalemia may not be associated with ECG changes.

If hyperkalemia is present, triamterene and hydrochlorothiazide capsules should be discontinued immediately and a thiazide alone should be substituted. If the serum potassium exceeds 6.5 mEq/L more vigorous therapy is required. The clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution, and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered.

Persistent hyperkalemia may require dialysis.

The development of hyperkalemia associated with potassium-sparing diuretics is accentuated in the presence of renal impairment (see CONTRAINDICATIONS). Patients with mild renal functional impairment should not receive this drug without frequent and continuing monitoring of serum electrolytes. Cumulative drug effects may be observed in patients with impaired renal function. The renal clearances of hydrochlorothiazide and the pharmacologically active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have been shown to be reduced and the plasma levels increased following administration of triamterene and hydrochlorothiazide to elderly patients and patients with impaired renal function.

Hyperkalemia has been reported in diabetic patients with the use of potassium-sparing agents even in the absence of apparent renal impairment. Accordingly, serum electrolytes must be frequently monitored if triamterene and hydrochlorothiazide capsules are used in diabetic patients.

Metabolic or Respiratory Acidosis

Potassium-sparing therapy should also be avoided in severely ill patients in whom respiratory or metabolic acidosis may occur. Acidosis may be associated with rapid elevations in serum potassium levels. If triamterene and hydrochlorothiazide capsules are employed, frequent evaluations of acid/base balance and serum electrolytes are necessary.

Acute Myopia and Secondary Angle-Closure Glaucoma

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

PRECAUTIONS

Diabetes

Caution should be exercised when administering triamterene and hydrochlorothiazide capsules to patients with diabetes, since thiazides may cause hyperglycemia, glycosuria, and alter insulin requirements in diabetes. Also, diabetes mellitus may become manifest during thiazide administration.

Impaired Hepatic Function

Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate hepatic coma in patients with severe liver disease. Potassium depletion induced by the thiazide may be important in this connection. Administer triamterene and hydrochlorothiazide capsules cautiously and be alert for early signs of impending coma such as confusion, drowsiness, and tremor; if mental confusion increases, discontinue triamterene and hydrochlorothiazide capsules for a few days. Attention must be given to

other factors that may precipitate hepatic coma, such as blood in the gastrointestinal tract or pre-existing potassium depletion.

Hypokalemia

Hypokalemia is uncommon with triamterene and hydrochlorothiazide capsules; but, should it develop, corrective measures should be taken such as potassium supplementation or increased intake of potassium-rich foods. Institute such measures cautiously with frequent determinations of serum potassium levels, especially in patients receiving digitalis or with a history of cardiac arrhythmias. If serious hypokalemia (serum potassium less than 3 mEq/L) is demonstrated by repeat serum potassium determinations, triamterene and hydrochlorothiazide capsules should be discontinued and potassium chloride supplementation initiated. Less serious hypokalemia should be evaluated with regard to other coexisting conditions and treated accordingly.

Electrolyte Imbalance

Electrolyte imbalance, often encountered in conditions such as heart failure, renal disease, or cirrhosis of the liver, may also be aggravated by diuretics and should be considered during therapy with triamterene and hydrochlorothiazide when using high doses for prolonged periods or in patients on a salt-restricted diet. Serum determinations of electrolytes should be performed and are particularly important if the patient is vomiting excessively or receiving fluids parenterally. Possible fluid and electrolyte imbalance may be indicated by warning signs such as: dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal symptoms.

Hypochloremia

Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Renal Stones

Triamterene has been found in renal stones in association with the other usual calculus components. Triamterene and hydrochlorothiazide capsules should be used with caution in patients with a history of renal stones.

Laboratory Tests

Serum Potassium

The normal adult range of serum potassium is 3.5 to 5.0 mEq/L with 4.5 mEq often being used for a reference point. If hypokalemia should develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods.

Institute such measures cautiously with frequent determinations of serum potassium

levels. Potassium levels persistently above 6 mEq/L require careful observation and treatment. Serum potassium levels do not necessarily indicate true body potassium concentration. A rise in plasma pH may cause a decrease in plasma potassium concentration and an increase in the intracellular potassium concentration. Discontinue corrective measures for hypokalemia immediately if laboratory determinations reveal an abnormal elevation of serum potassium.

Discontinue triamterene and hydrochlorothiazide capsules and substitute a thiazide diuretic alone until potassium levels return to normal.

Serum Creatinine and Blood Urea Nitrogen

Triamterene and hydrochlorothiazide may produce an elevated blood urea nitrogen (BUN) level, creatinine level, or both. This apparently is secondary to a reversible reduction of glomerular filtration rate or a depletion of intravascular fluid volume (prerenal azotemia) rather than renal toxicity; levels usually return to normal when triamterene and hydrochlorothiazide capsules is discontinued. If azotemia increases, discontinue triamterene and hydrochlorothiazide capsules. Periodic BUN or serum creatinine determinations should be made, especially in elderly patients and in patients with suspected or confirmed renal insufficiency.

Serum Protein-Bound Iodine

Thiazide may decrease serum protein-bound iodine (PBI) levels without sign of thyroid disturbance.

Parathyroid Function

Thiazides should be discontinued before carrying out tests for parathyroid function. Calcium excretion is decreased by thiazides. Pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as bone resorption and peptic ulceration have not been seen.

Drug Interactions

Angiotensin-Converting Enzyme Inhibitors

Potassium-sparing agents should be used with caution in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to an increased risk of hyperkalemia.

Oral Hypoglycemic Drugs

Concurrent use with chlorpropamide may increase the risk of severe hyponatremia.

Nonsteroidal Anti-inflammatory Drugs

A possible interaction resulting in acute renal failure has been reported in a few patients on triamterene and hydrochlorothiazide capsules when treated with indomethacin, a nonsteroidal anti-inflammatory agent. Caution is advised in administering nonsteroidal anti-inflammatory agents with triamterene and hydrochlorothiazide capsules.

Lithium

Lithium generally should not be given with diuretics because they reduce its renal clearance and increase the risk of lithium toxicity. Read prescribing information for lithium preparations before use of such concomitant therapy with triamterene and

hydrochlorothiazide capsules.

Surgical Considerations

Thiazides have been shown to decrease arterial responsiveness to norepinephrine (an effect attributed to loss of sodium). This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine (an effect attributed to potassium loss); consequently, caution should be observed in patients undergoing surgery

Other Considerations

Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect.

Thiazides may add to or potentiate the action of other antihypertensive drugs. See INDICATIONS AND USAGE for concomitant use with other antihypertensive drugs.

The effect of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary.

Triamterene and hydrochlorothiazide may raise the level of blood uric acid; dosage adjustments of antigout medication may be necessary to control hyperuricemia and gout.

The following agents given together with triamterene may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain potassium up to 30 mEq/L of plasma or up to 65 mEq/L of whole blood when stored for more than 10 days); low-salt milk (may contain potassium up to 60 mEq/L); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).

Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake.

Chronic or overuse of laxatives may reduce serum potassium levels by promoting excessive potassium loss from the intestinal tract; laxatives may interfere with the potassium-retaining effects of triamterene.

The effectiveness of methenamine may be decreased when used concurrently with hydrochlorothiazide because of alkalinization of the urine.

Information for Patients

Non-Melanoma Skin Cancer

Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening.

Drug/Laboratory Test Interactions

Triamterene and quinidine have similar fluorescence spectra; thus, triamterene and hydrochlorothiazide will interfere with the fluorescent measurement of quinidine.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Long-term studies have not been conducted with the triamterene/hydrochlorothiazide combination or with triamterene alone.

Hydrochlorothiazide: Two-year feeding studies in mice and rats, conducted under the auspices of the National Toxicology Program (NTP) treated mice and rats with doses of hydrochlorothiazide up to 600 and 100 mg/kg/day, respectively. On a body-weight basis, these doses are 600 times (in mice) and 100 times (in rats) the maximum recommended human dose (MRHD) for the hydrochlorothiazide component of triamterene and hydrochlorothiazide capsules at 50 mg/day (or 1 mg/kg/day based on 50-kg individuals). On the basis of body surface area, these doses are 56 times (in mice) and 21 times (in rats) the MRHD. These studies uncovered no evidence of carcinogenic potential of hydrochlorothiazide in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice.

Mutagenesis

Studies of the mutagenic potential of the triamterene/hydrochlorothiazide combination or of triamterene alone have not been performed.

Hydrochlorothiazide: Hydrochlorothiazide was not genotoxic in *in vitro*assays using strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 of *Salmonella typhimurium* (the Ames test); in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations; or in *in vivo*assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the *Drosophila* sex-linked recessive lethal trait gene. Positive test results were obtained in the *in vitro*CHO Sister Chromatid Exchange (clastogenicity) test and in the mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43 to 1,300 mcg/mL. Positive test results were also obtained in the *Aspergillus nidulans* nondisjunction assay, using an unspecified concentration of hydrochlorothiazide.

Impairment of Fertility

Studies of the effects of the triamterene/hydrochlorothiazide combination or of triamterene alone on animal reproductive function have not been conducted.

Hydrochlorothiazide: Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation. Corresponding multiples of the MRHD are 100 (mice) and 4 (rats) on the basis of body weight and 9.4 (mice) and 0.8 (rats) on the basis of body surface area.

Pregnancy

Teratogenic Effects

Triamterene and Hydrochlorothiazide: Animal reproduction studies to determine the potential for fetal harm by triamterene and hydrochlorothiazide have not been conducted. However, a One Generation Study in the rat approximated composition of triamterene and hydrochlorothiazide capsules by using a 1:1 ratio of triamterene to hydrochlorothiazide (30:30 mg/kg/day); there was no evidence of teratogenicity at those

doses which were, on a body-weight basis, 15 and 30 times, respectively, the MRHD, and on the basis of body surface area, 3.1 and 6.2 times, respectively, the MRHD.

The safe use of triamterene and hydrochlorothiazide capsules in pregnancy has not been established since there are no adequate and well-controlled studies with triamterene and hydrochlorothiazide in pregnant women. Triamterene and hydrochlorothiazide capsules should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

Triamterene: Reproduction studies have been performed in rats at doses as high as 20 times the MRHD on the basis of body weight and 6 times the human dose on the basis of body surface area without evidence of harm to the fetus due to triamterene.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Hydrochlorothiazide: Hydrochlorothiazide was orally administered to pregnant mice and rats during respective periods of major organogenesis at doses up to 3,000 and 1,000 mg/kg/day, respectively. At these doses, which are multiples of the MRHD equal to 3,000 for mice and 1,000 for rats, based on body weight, and equal to 282 for mice and 206 for rats, based on body surface area, there was no evidence of harm to the fetus.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nonteratogenic Effects

Thiazides and triamterene have been shown to cross the placental barrier and appear in cord blood. The use of thiazides and triamterene in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, pancreatitis, thrombocytopenia, and possible other adverse reactions which have occurred in the adult.

Nursing Mothers

Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk; this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Adverse effects are listed in decreasing order of severity.

Hypersensitivity: Anaphylaxis, rash, urticaria, subacute cutaneous lupus erythematosus-like reactions, photosensitivity.

Cardiovascular: Arrhythmia, postural hypotension.

Metabolic: Diabetes mellitus, hyperkalemia, hypokalemia, hyponatremia, acidosis,

hypercalcemia, hyperglycemia, glycosuria, hyperuricemia, hypochloremia.

Gastrointestinal:Jaundice and/or liver enzyme abnormalities, pancreatitis, nausea and vomiting, diarrhea, constipation, abdominal pain.

Renal:Acute renal failure (one case of irreversible renal failure has been reported), interstitial nephritis, renal stones composed primarily of triamterene, elevated BUN and serum creatinine, abnormal urinary sediment.

Hematologic:Leukopenia, thrombocytopenia and purpura, megaloblastic anemia.

Musculoskeletal:Muscle cramps.

Central Nervous System:Weakness, fatigue, dizziness, headache, dry mouth.

Miscellaneous:Impotence, sialadenitis. Thiazides alone have been shown to cause the following additional adverse reactions:

Central Nervous System:Paresthesias, vertigo.

Ophthalmic:Xanthopsia, transient blurred vision.

Respiratory:Allergic pneumonitis, pulmonary edema, respiratory distress.

Other:Necrotizing vasculitis, exacerbation of lupus.

Hematologic:Aplastic anemia, agranulocytosis, hemolytic anemia.

Neonate and infancy:Thrombocytopenia and pancreatitis-rarely, in newborns whose mothers have received thiazides during pregnancy.

Skin:Erythema multiforme, including Stevens-Johnson syndrome; exfoliative dermatitis, including toxic epidermal necrolysis.

Postmarketing Experience

Non-Melanoma Skin Cancer

Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of $\geq 50,000$ mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.

To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

The usual dose of triamterene and hydrochlorothiazide capsules is 1 or 2 capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect (see WARNINGS, Hyperkalemia).

OVERDOSAGE

Electrolyte imbalance is the major concern (see WARNINGS). Symptoms reported include: polyuria, nausea, vomiting, weakness, lassitude, fever, flushed face, and hyperactive deep tendon reflexes. If hypotension occurs, it may be treated with pressor agents such as levarterenol to maintain blood pressure. Carefully evaluate the electrolyte pattern and fluid balance. Induce immediate evacuation of the stomach through emesis or gastric lavage. There is no specific antidote.

Reversible acute renal failure following ingestion of 50 tablets of a product containing a combination of 50 mg triamterene and 25 mg hydrochlorothiazide has been reported. Although triamterene is largely protein-bound (approximately 67%), there may be some benefit to dialysis in cases of overdosage.

HOW SUPPLIED

Triamterene and Hydrochlorothiazide Capsules USP, 37.5 mg/25 mg are light yellow to yellow colored powder filled in size '4' empty hard gelatin capsule having yellow opaque colored cap imprinted with "855" in black ink and white opaque colored body and are supplied as follows:

NDC: 70518-4270-00

PACKAGING: 90 in 1 BOTTLE PLASTIC

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Rerepackaged and Distributed By:

Remedy Repack, Inc.

625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

DRUG: Triamterene and Hydrochlorothiazide

GENERIC: Triamterene and Hydrochlorothiazide

DOSAGE: CAPSULE

ADMINISTRATION: ORAL

NDC: 70518-4270-0

COLOR: yellow

SHAPE: CAPSULE

SCORE: No score

SIZE: 14 mm

IMPRINT: 855

PACKAGING: 90 in 1 BOTTLE, PLASTIC

ACTIVE INGREDIENT(S):

- TRIAMTERENE 37.5mg in 1
- HYDROCHLOROTHIAZIDE 25mg in 1

INACTIVE INGREDIENT(S):

- CELLULOSE, MICROCRYSTALLINE
- CITRIC ACID MONOHYDRATE
- CROSCARMELLOSE SODIUM
- FERRIC OXIDE YELLOW
- FERROSOFERRIC OXIDE
- GELATIN
- GLYCINE
- HYPROMELLOSE 2910 (3 MPA.S)
- MAGNESIUM STEARATE
- POTASSIUM HYDROXIDE
- SHELLAC
- SILICON DIOXIDE
- SODIUM LAURYL SULFATE
- TITANIUM DIOXIDE

Triamterene / HCTZ Capsule

37.5mg / 25 mg

QTY: 90 Capsules

NDC #: 70518-4270-00

Expires:

LOT #:

Org NDC: 72578-0090-10

MFG: Viona Pharmaceuticals Inc,
Cranford, NJ 07016

Keep this and all medication out
of the reach of children
Store at 20-25°C (68-77°F);
excursions permitted to 15-30°C
(59-86°F) [See USP]

Capsule YELLOW/WHITE 855

Usual Dosage: See Insert

Repackaged By:

RemedyRepack Inc.,
Indiana, PA 15701, 724.465.8762

14-21-0000
14-21-0001
14-21-0002
14-21-0003
14-21-0004
14-21-0005
14-21-0006
14-21-0007
14-21-0008
14-21-0009
14-21-0010
14-21-0011
14-21-0012
14-21-0013
14-21-0014
14-21-0015
14-21-0016
14-21-0017
14-21-0018
14-21-0019
14-21-0020
14-21-0021
14-21-0022
14-21-0023
14-21-0024
14-21-0025
14-21-0026
14-21-0027
14-21-0028
14-21-0029
14-21-0030
14-21-0031
14-21-0032
14-21-0033
14-21-0034
14-21-0035
14-21-0036
14-21-0037
14-21-0038
14-21-0039
14-21-0040
14-21-0041
14-21-0042
14-21-0043
14-21-0044
14-21-0045
14-21-0046
14-21-0047
14-21-0048
14-21-0049
14-21-0050
14-21-0051
14-21-0052
14-21-0053
14-21-0054
14-21-0055
14-21-0056
14-21-0057
14-21-0058
14-21-0059
14-21-0060
14-21-0061
14-21-0062
14-21-0063
14-21-0064
14-21-0065
14-21-0066
14-21-0067
14-21-0068
14-21-0069
14-21-0070
14-21-0071
14-21-0072
14-21-0073
14-21-0074
14-21-0075
14-21-0076
14-21-0077
14-21-0078
14-21-0079
14-21-0080
14-21-0081
14-21-0082
14-21-0083
14-21-0084
14-21-0085
14-21-0086
14-21-0087
14-21-0088
14-21-0089
14-21-0090
14-21-0091
14-21-0092
14-21-0093
14-21-0094
14-21-0095
14-21-0096
14-21-0097
14-21-0098
14-21-0099
14-21-0100
14-21-0101
14-21-0102
14-21-0103
14-21-0104
14-21-0105
14-21-0106
14-21-0107
14-21-0108
14-21-0109
14-21-0110
14-21-0111
14-21-0112
14-21-0113
14-21-0114
14-21-0115
14-21-0116
14-21-0117
14-21-0118
14-21-0119
14-21-0120
14-21-0121
14-21-0122
14-21-0123
14-21-0124
14-21-0125
14-21-0126
14-21-0127
14-21-0128
14-21-0129
14-21-0130
14-21-0131
14-21-0132
14-21-0133
14-21-0134
14-21-0135
14-21-0136
14-21-0137
14-21-0138
14-21-0139
14-21-0140
14-21-0141
14-21-0142
14-21-0143
14-21-0144
14-21-0145
14-21-0146
14-21-0147
14-21-0148
14-21-0149
14-21-0150
14-21-0151
14-21-0152
14-21-0153
14-21-0154
14-21-0155
14-21-0156
14-21-0157
14-21-0158
14-21-0159
14-21-0160
14-21-0161
14-21-0162
14-21-0163
14-21-0164
14-21-0165
14-21-0166
14-21-0167
14-21-0168
14-21-0169
14-21-0170
14-21-0171
14-21-0172
14-21-0173
14-21-0174
14-21-0175
14-21-0176
14-21-0177
14-21-0178
14-21-0179
14-21-0180
14-21-0181
14-21-0182
14-21-0183
14-21-0184
14-21-0185
14-21-0186
14-21-0187
14-21-0188
14-21-0189
14-21-0190
14-21-0191
14-21-0192
14-21-0193
14-21-0194
14-21-0195
14-21-0196
14-21-0197
14-21-0198
14-21-0199
14-21-0200
14-21-0201
14-21-0202
14-21-0203
14-21-0204
14-21-0205
14-21-0206
14-21-0207
14-21-0208
14-21-0209
14-21-0210
14-21-0211
14-21-0212
14-21-0213
14-21-0214
14-21-0215
14-21-0216
14-21-0217
14-21-0218
14-21-0219
14-21-0220
14-21-0221
14-21-0222
14-21-0223
14-21-0224
14-21-0225
14-21-0226
14-21-0227
14-21-0228
14-21-0229
14-21-0230
14-21-0231
14-21-0232
14-21-0233
14-21-0234
14-21-0235
14-21-0236
14-21-0237
14-21-0238
14-21-0239
14-21-0240
14-21-0241
14-21-0242
14-21-0243
14-21-0244
14-21-0245
14-21-0246
14-21-0247
14-21-0248
14-21-0249
14-21-0250
14-21-0251
14-21-0252
14-21-0253
14-21-0254
14-21-0255
14-21-0256
14-21-0257
14-21-0258
14-21-0259
14-21-0260
14-21-0261
14-21-0262
14-21-0263
14-21-0264
14-21-0265
14-21-0266
14-21-0267
14-21-0268
14-21-0269
14-21-0270
14-21-0271
14-21-0272
14-21-0273
14-21-0274
14-21-0275
14-21-0276
14-21-0277
14-21-0278
14-21-0279
14-21-0280
14-21-0281
14-21-0282
14-21-0283
14-21-0284
14-21-0285
14-21-0286
14-21-0287
14-21-0288
14-21-0289
14-21-0290
14-21-0291
14-21-0292
14-21-0293
14-21-0294
14-21-0295
14-21-0296
14-21-0297
14-21-0298
14-21-0299
14-21-0300
14-21-0301
14-21-0302
14-21-0303
14-21-0304
14-21-0305
14-21-0306
14-21-0307
14-21-0308
14-21-0309
14-21-0310
14-21-0311
14-21-0312
14-21-0313
14-21-0314
14-21-0315
14-21-0316
14-21-0317
14-21-0318
14-21-0319
14-21-0320
14-21-0321
14-21-0322
14-21-0323
14-21-0324
14-21-0325
14-21-0326
14-21-0327
14-21-0328
14-21-0329
14-21-0330
14-21-0331
14-21-0332
14-21-0333
14-21-0334
14-21-0335
14-21-0336
14-21-0337
14-21-0338
14-21-0339
14-21-0340
14-21-0341
14-21-0342
14-21-0343
14-21-0344
14-21-0345
14-21-0346
14-21-0347
14-21-0348
14-21-0349
14-21-0350
14-21-0351
14-21-0352
14-21-0353
14-21-0354
14-21-0355
14-21-0356
14-21-0357
14-21-0358
14-21-0359
14-21-0360
14-21-0361
14-21-0362
14-21-0363
14-21-0364
14-21-0365
14-21-0366
14-21-0367
14-21-0368
14-21-0369
14-21-0370
14-21-0371
14-21-0372
14-21-0373
14-21-0374
14-21-0375
14-21-0376
14-21-0377
14-21-0378
14-21-0379
14-21-0380
14-21-0381
14-21-0382
14-21-0383
14-21-0384
14-21-0385
14-21-0386
14-21-0387
14-21-0388
14-21-0389
14-21-0390
14-21-0391
14-21-0392
14-21-0393
14-21-0394
14-21-0395
14-21-0396
14-21-0397
14-21-0398
14-21-0399
14-21-0400
14-21-0401
14-21-0402
14-21-0403
14-21-0404
14-21-0405
14-21-0406
14-21-0407
14-21-0408
14-21-0409
14-21-0410
14-21-0411
14-21-0412
14-21-0413
14-21-0414
14-21-0415
14-21-0416
14-21-0417
14-21-0418
14-21-0419
14-21-0420
14-21-0421
14-21-0422
14-21-0423
14-21-0424
14-21-0425
14-21-0426
14-21-0427
14-21-0428
14-21-0429
14-21-0430
14-21-0431
14-21-0432
14-21-0433
14-21-0434
14-21-0435
14-21-0436
14-21-0437
14-21-0438
14-21-0439
14-21-0440
14-21-0441
14-21-0442
14-21-0443
14-21-0444
14-21-0445
14-21-0446
14-21-0447
14-21-0448
14-21-0449
14-21-0450
14-21-0451
14-21-0452
14-21-0453
14-21-0454
14-21-0455
14-21-0456
14-21-0457
14-21-0458
14-21-0459
14-21-0460
14-21-0461
14-21-0462
14-21-0463
14-21-0464
14-21-0465
14-21-0466
14-21-0467
14-21-0468
14-21-0469
14-21-0470
14-21-0471
14-21-0472
14-21-0473
14-21-0474
14-21-0475
14-21-0476
14-21-0477
14-21-0478
14-21-0479
14-21-0480
14-21-0481
14-21-0482
14-21-0483
14-21-0484
14-21-0485
14-21-0486
14-21-0487
14-21-0488
14-21-0489
14-21-0490
14-21-0491
14-21-0492
14-21-0493
14-21-0494
14-21-0495
14-21-0496
14-21-0497
14-21-0498
14-21-0499
14-21-0500
14-21-0501
14-21-0502
14-21-0503
14-21-0504
14-21-0505
14-21-0506
14-21-0507
14-21-0508
14-21-0509
14-21-0510
14-21-0511
14-21-0512
14-21-0513
14-21-0514
14-21-0515
14-21-0516
14-21-0517
14-21-0518
14-21-0519
14-21-0520
14-21-0521
14-21-0522
14-21-0523
14-21-0524
14-21-0525
14-21-0526
14-21-0527
14-21-0528
14-21-0529
14-21-0530
14-21-0531
14-21-0532
14-21-0533
14-21-0534
14-21-0535
14-21-0536
14-21-0537
14-21-0538
14-21-0539
14-21-0540
14-21-0541
14-21-0542
14-21-0543
14-21-0544
14-21-0545
14-21-0546
14-21-0547
14-21-0548
14-21-0549
14-21-0550
14-21-0551
14-21-0552
14-21-0553
14-21-0554
14-21-0555
14-21-0556
14-21-0557
14-21-0558
14-21-0559
14-21-0560
14-21-0561
14-21-0562
14-21-0563
14-21-0564
14-21-0565
14-21-0566
14-21-0567
14-21-0568
14-21-0569
14-21-0570
14-21-0571
14-21-0572
14-21-0573
14-21-0574
14-21-0575
14-21-0576
14-21-0577
14-21-0578
14-21-0579
14-21-0580
14-21-0581
14-21-0582
14-21-0583
14-21-0584
14-21-0585
14-21-0586
14-21-0587
14-21-0588
14-21-0589
14-21-0590
14-21-0591
14-21-0592
14-21-0593
14-21-0594
14-21-0595
14-21-0596
14-21-0597
14-21-0598
14-21-0599
14-21-0600
14-21-0601
14-21-0602
14-21-0603
14-21-0604
14-21-0605
14-21-0606
14-21-0607
14-21-0608
14-21-0609
14-21-0610
14-21-0611
14-21-0612
14-21-0613
14-21-0614
14-21-0615
14-21-0616
14-21-0617
14-21-0618
14-21-0619
14-21-0620
14-21-0621
14-21-0622
14-21-0623
14-21-0624
14-21-0625
14-21-0626
14-21-0627
14-21-0628
14-21-0629
14-21-0630
14-21-0631
14-21-0632
14-21-0633
14-21-0634
14-21-0635
14-21-0636
14-21-0637
14-21-0638
14-21-0639
14-21-0640
14-21-0641
14-21-0642
14-21-0643
14-21-0644
14-21-0645
14-21-0646
14-21-0647
14-21-0648
14-21-0649
14-21-0650
14-21-0651
14-21-0652
14-21-0653
14-21-0654
14-21-0655
14-21-0656
14-21-0657
14-21-0658
14-21-0659
14-21-0660
14-21-0661
14-21-0662
14-21-0663
14-21-0664
14-21-0665
14-21-0666
14-21-0667
14-21-0668
14-21-0669
14-21-0670
14-21-0671
14-21-0672
14-21-0673
14-21-0674
14-21-0675
14-21-0676
14-21-0677
14-21-0678
14-21-0679
14-21-0680
14-21-0681
14-21-0682
14-21-0683
14-21-0684
14-21-0685
14-21-0686
14-21-0687
14-21-0688
14-21-0689
14-21-0690
14-21-0691
14-21-0692
14-21-0693
14-21-0694
14-21-0695
14-21-0696
14-21-0697
14-21-0698
14-21-0699
14-21-0700
14-21-0701
14-21-0702
14-21-0703
14-21-0704
14-21-0705
14-21-0706
14-21-0707
14-21-0708
14-21-0709
14-21-0710
14-21-0711
14-21-0712
14-21-0713
14-21-0714
14-21-0715
14-21-0716
14-21-0717
14-21-0718
14-21-0719
14-21-0720
14-21-0721
14-21-0722
14-21-0723
14-21-0724
14-21-0725
14-21-0726
14-21-0727
14-21-0728
14-21-0729
14-21-0730
14-21-0731
14-21-0732
14-21-0733
14-21-0734
14-21-0735
14-21-0736
14-21-0737
14-21-0738
14-21-0739
14-21-0740
14-21-0741
14-21-0742
14-21-0743
14-21-0744
14-21-0745
14-21-0746
14-21-0747
14-21-0748
14-21-0749
14-21-0750
14-21-0751
14-21-0752
14-21-0753
14-21-0754
14-21-0755
14-21-0756
14-21-0757
14-21-0758
14-21-0759
14-21-0760
14-21-0761
14-21-0762
14-21-0763
14-21-0764
14-21-0765
14-21-0766
14-21-0767
14-21-0768
14-21-0769
14-21-0770
14-21-0771
14-21-0772
14-21-0773
14-21-0774
14-21-0775
14-21-0776
14-21-0777
14-21-0778
14-21-0779
14-21-0780
14-21-0781
14-21-0782
14-21-0783
14-21-0784
14-21-0785
14-21-0786
14-21-0787
14-21-0788
14-21-0789
14-21-0790
14-21-0791
14-21-0792
14-21-0793
14-21-0794
14-21-0795
14-21-0796
14-21-0797
14-21-0798
14-21-0799
14-21-0800
14-21-0801
14-21-0802
14-21-0803
14-21-0804
14-21-0805
14-21-0806
14-21-0807
14-21-0808
14-21-0809
14-21-0810
14-21-0811
14-21-0812
14-21-0813
14-21-0814
14-21-0815
14-21-0816
14-21-0817
14-21-0818
14-21-0819
14-21-0820
14-21-0821
14-21-0822
14-21-0823
14-21-0824
14-21-0825
14-21-0826
14-21-0827
14-21-0828
14-21-0829
14-21-0830
14-21-0831
14-21-0832
14-21-0833
14-21-0834
14-21-0835
14-21-0836
14-21-0837
14-21-0838
14-21-0839
14-21-0840
14-21-0841
14-21-0842
14-21-0843
14-21-0844
14-21-0845
14-21-0846
14-21-0847
14-21-0848
14-21-0849
14-21-0850
14-21-0851
14-21-0852
14-21-0853
14-21-0854
14-21-0855
14-21-0856
14-21-0857
14-21-0858
14-21-0859
14-21-0860
14-21-0861
14-2

Inactive Ingredients

Ingredient Name	Strength
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
FERRIC OXIDE YELLOW (UNII: EX438O2MRT)	
FERROSOFERRIC OXIDE (UNII: XM0M87F357)	
GELATIN (UNII: 2G86QN327L)	
GLYCINE (UNII: TE7660XO1C)	
HYPROMELLOSE 2910 (3 MPAS) (UNII: 0VUT3PMY82)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SHELLAC (UNII: 46N107B71O)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	

Product Characteristics

Color	yellow (yellow opaque colored cap) , white (white opaque colored body)	Score	no score
Shape	CAPSULE	Size	14mm
Flavor		Imprint Code	855
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70518-4270-0	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	01/27/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA208358	01/27/2025	

Labeler - REMEDYREPACK INC. (829572556)